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Other names: CDKN2a; p16; INK4; p16- INK4a; 




The gene encompasses 6.6 kb of DNA; 3 exons. 
Transcription 
471 nucleotides mRNA. The CDKN2 gene generates 
several transcript variants from different promoters. 
Each transcript differs in its first exon (E1), and utilizes 
alternate polyadenylation sites. E1-alpha, which is 
spliced into the common exons E2 and E3, gives rise to 
the p16-INK4 transcript. A putative DNA replication 
origin has been identified in close proximity of 
INK4/Arf locus that appears to transcriptionally rep ss 
p16 in a manner dependent on CDC6. 
Protein 
Description 
156 amino acids; 16.5 kDa protein. 
Expression 
Moderately expressed in many organs as thymus, liver, 
pancreas, prostate, lung, or kidney. 
Function 
P16-INK4a interacts strongly with cyclin-dependent 
kinase 4 and cyclin-dependent kinase 6 and inhibits 
their ability to interact with cyclins D. P16-INK4a 
induces cell cycle arrest at G1 and G2/M checkpoints, 
blocking them from phosphorylating RB1 and 
preventing exit from G1 phase of the cell cycle. P16-
INK4a could act as a negative regulator of normal cells 
proliferation. 
Homology 
Belongs to the cdkn2 cyclin-dependent kinase inhibitor 
family. 
Implicated in 
Cutaneous malignant melanoma 2 
(CMM2) 
Disease 
Malignant melanoma arises de novo or from a 
preexisting benign nevus, which occurs most often in 
the skin but also may involve other sites. 
Oncogenesis 
Familial melanoma (comprising between 8 and 12% of 
all melanoma cases) is a genodermatosis transmitted as 
an autosomal dominant trait. CDKN2a has been 
identified as a major susceptibility gene for melanoma. 
However this gene accounts for a minority of familial 
melanoma. P16 is functionally inactivated by mutations 
or deletions, however, because many such mutations 
occur in exon 2, they can potentially also affect the 
alternative reading frame (ARF) protein. 
Familial atypical multiple mole 
melanoma carcinoma syndrome 
(FAMMM) 
Disease 
Patients with the FAMMM syndrome are genetically 
loaded with an increased risk of developing melanoma 
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and other malignant neoplasms, for example, a 
pancreatic cancer. 
Oncogenesis 
FAMMM syndrome is an autosomal dominant disorder 
with variable incomplete penetrance of the clinical 
phenotypes. Germline mutations in the p16-INK4a 




Defects in CDKN2a are involved in tumor formation in 
a wide range of tissues. 
Prognosis 
Aberrant p16 expression is associated with more 
aggressive behavior. 
Oncogenesis 
LOH on 9p21 is one of the most frequent genetic 
alterations identified in human cancer. However, point 
mutations of p16 on the other chromosome are 
relatively rare. Promoter methylation appears as the 
commonest mechanism of p16 gene inactivation. 
Aging 
Note: Expression of p16 increases markedly with aging 
in many human tissues. This finding has led to the 
proposal that p16 expression could be used as a 
biomarker of physiologic, as opposed to chronologic, 
age. It was suggested that an age-induced increase in 
p16 expression contributes to the decline of replicative 
potential of certain self-renewing compartments with 
aging. 
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